International Stem Cell Corp. (ISC) (OTCBB:ISCO) announced Tuesday its plans to present at the American Society of Gene and Cell Therapy's Annual Meeting in Seattle, Washington, this month.
Two of the company's scientists will present the results of the company's experiements on the therapeutic use of human parthenogenetic stem cells (hpSC), which have the capacity to essentially become almost any cell type in the body.
International Stem Cell's scientists have developed the first hpSC line that can be a source of therapeutic cells, with minimal immune rejection. The company's parthenogenetic process to create stem cells avoids ethical issues by using unfertilized human eggs.
At the upcoming meeting, vice president Dr. Ruslan Semechkin will give a presentation called "Neutral Stem Cells of Parthenogenetic Origin" on May 19.
Meanwhile, on May 21, director of research and therapeutic development, Dr. Nikolay Turovets, is slated to introduce a poster presentation entitled "An in vitro Analog of the Primitive Streak to Derive High-Purity Definitive Endoderm Lineages Uncontaminated with Undifferentiated Cells".
The American Society of Gene & Cell Therapy (ASGCT) is a not-for-profit medical and scientific organization that is dedicated to developing and applying genetic and cellular therapies. The ASGCT presents new findings in gene and cell therapies at its annual meeting, attended by over 2,000 scientists and post-doctoral fellows worldwide.